Noninvasive prenatal Ariosa Diagnostics specializes in non-invasive prenatal testing with the Harmony Prenatal Test, offering higher accuracy and affordability to expecting mothers and a potential sales angle targeting OB/GYN clinics, maternal-fetal medicine specialists, and insurance partners.

Growth potential With a mid-sized team and revenue in a range suggesting profitability, there is room to scale through expanded lab services, strategic partnerships, and enterprise licensing opportunities with large health systems and diagnostic networks.

Competitive landscape Historical patent litigation involving fetal DNA extraction indicates a high-stakes environment; this signals a need for robust IP-aware collaboration strategies, co-development, or alternative assay approaches when approaching customers wary of litigation risk.

Strategic partnerships Previous acquisition by Roche and ongoing patent disputes imply potential for alliance discussions with big pharma, diagnostics firms, or CROs seeking complementary cfDNA capabilities or broader service offerings in maternal-fetal health.

Market positioning Harmony Test’s value proposition centers on reducing invasive procedures; sales efforts can emphasize maternal-fetal health outcomes, patient experience, payer adoption, and early actionable results to drive negotiation with clinics and health plans.